LIGAND AND SIRNA MEDIATED NANOMEDICINE FOR ENHANCED CHEMOTHERAPY

Abstract

TRADITIONAL CHEMOTHERAPY HAS TWO MAJOR DRAWBACKS: NON-SPECIFICITY AND DRUG RESISTANCE. NANOCARRIER FORMULATION IS TO DATE THE MOST PROMISING FORMULATION STRATEGY WHICH ENABLES SUSTAINED, CONTROLLED, AND TARGETED DELIVERY OF THERAPEUTIC AGENTS. LIGAND CONJUGATION CAN REDUCE NON-SPECIFICITY BY SELECTIVELY INTERACTING WITH THE TUMOR CELLS WHICH HAVE AN OVEREXPRESSION OF THE RECEPTORS. IN THE THESIS, WE DEVELOPED STRATEGIES TO PRECISELY CONTROL AND QUANTIFY THE TARGETING EFFECT OF HERCEPTIN CONJUGATED VITAMIN E TPGS COPOLYMER NANOPARTICLES. SIRNA MEDIATED NANOMEDICINE, THE NANOCARRIER FORMULATION OF ANTICANCER DRUG AND THE SIRNA WHICH SILENCES THE GENE RESPONSIBLE FOR THE DRUG RESISTANCE, CAN BE A STRATEGY TO ALLEVIATE DRUG RESISTANCE. IN THE THESIS, WE DEMONSTRATED ON MULTIPLE CELL LINES THAT THE CO-DELIVERY OF POLO-LIKE KINASE 1 SIRNA (SIPLK1) AND ANTICANCER DRUGS IN HERCEPTIN CONJUGATED VITAMIN E TPGS BASED MICELLES AND NANOGELS SIGNIFICANTLY IMPROVED THE THERAPEUTIC EFFICACY OF THE DRU